Company performance
Add to research
Current Price
as of Apr 21, 2025$0.50
P/E Ratio
N/A
Market Cap
$72.99M
Description
Add to research
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.
Metrics
Add to research
Overview
- HQLouisville, CO
- SectorHealth Services
- IndustryMedical/Nursing Services
- TickerBDSX
- Price$0.5-8.93%
Trading Information
- Market cap$72.99M
- Float50.62%
- Average Daily Volume (1m)355,585
- Average Daily Volume (3m)425,668
- EPS-$0.33
Company
- Revenue$71.32M
- Rev growth (1yr)45.30%
- Net income-$42.93M
- Gross margin70.65%
- EBITDA margin-40.39%
- EBITDA-$28.80M
- EV$234.03M
- EV/Revenue3.28
- P/EN/A
- P/S0.91
- P/B3.48
- Debt/Equity296.88
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset